Ruishi Biomedical Co.
Latest round
- Series A
Last raised
- May 2022
Total raised
- $100M
Investors
- 5
About Ruishi Biomedical Co.
Based in Shanghai, China, and founded in 2018, Reistone Biopharma operates as a biopharmaceutical company that focuses on developing medicines for immuno-inflammatory diseases. The company's co-founder and CEO, Min Wang Irwin was formerly a venture partner at Qiming Venture Capital. The company's Chief Medical Officer, Aik Goh is a UK General Medical Council (GMC) registered doctor, and worked in GSK for 10 years. The company has offices in Beijing and the US. The company is executing global multi-center clinical programs of SHR 0302, including oral and topical dosage forms, for the treatment of Inflammatory Bowel Diseases (IBD) such as Ulcerative colitis (UC) and Crohn's disease (CD), as well as inflammatory skin diseases such as Atopic Dermatitis, Alopecia Areata and Vitiligo.
Who invested in Ruishi Biomedical Co.
5 investors across 1 round
See all investors in Ruishi Biomedical Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 9, 2022
Amount
$100M
Investors
Questions about Ruishi Biomedical Co.
Who invested in Ruishi Biomedical Co.?
Ruishi Biomedical Co. has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ruishi Biomedical Co. raised?
Ruishi Biomedical Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ruishi Biomedical Co. last raise money?
Ruishi Biomedical Co.'s most recent round on record is a Series A, in May 2022.
What does Ruishi Biomedical Co. do?
Based in Shanghai, China, and founded in 2018, Reistone Biopharma operates as a biopharmaceutical company that focuses on developing medicines for immuno-inflammatory diseases.
Where is Ruishi Biomedical Co. headquartered?
Ruishi Biomedical Co. is headquartered in Shanghai, China.
Which VCs invest in companies like Ruishi Biomedical Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Ruishi Biomedical Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ruishi Biomedical Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.